We're working on something new at CrunchBase. Edits have been disabled for a few days, but you can still contact us for urgent changes.
Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteheartmetabolics.com
CategoryBioTech
Emailinfo@heartmetabol...
Employees

Offices

People

Funding

Tags

Heart Metabolics

Heart Metabolics Limited, a London, UK-based developer of a drug to treat heart failure for hypertrophic cardiomyopathy patients. Founded by Professor Michael Frenneaux and Dr. Houman Ashrafian, the company recently (June 2012) obtained orphan designation from the FDA for the use of perhexiline as first line treatment for moderate-to-severe heart failure due to HCM. It has also in-licensed a new chemical entity drug candidate from The University of Adelaide (Australia) for the treatment of heart failure.

Recent Milestones

Videos

Screenshots

Sources

  1. Heart Metabolics Closes $4M Series A Funding (finsmes.com) [edit]
  2. Heart Metabolics Completes $20M Series A Financing (finsmes.com) [edit]
Edit This Page
Last Edited 4/17/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy